Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.

699Background: AcSe Nivolumab (N), is a non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in patients (pts) with specific rare cancers (...